Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation

The endothelial cell‐specific mitogen vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) represents a central regulator of cutaneous angiogenesis. Increased VPF/VEGF expression has recently been reported in psoriatic skin and healing wounds, both conditions in which transforming growth factor‐α (TGFα) and its ligand, the epidermal growth factor receptor, are markedly up‐regulated. Since TGFα strongly induces VPF/VEGF synthesis in keratinocytes, TGFα‐mediated VPF/VEGF expression is likely to play a significant role in the initiation and maintenance of increased vascular hyperpermeability and hyperproliferation in skin biology. The objectives of the present studies were to determine the molecular mechanisms responsible for TGFα‐induced transcriptional activation of the VPF/VEGF gene. We have identified a GC‐rich TGFα‐responsive region between −88 bp and −65 bp of the VPF/VEGF promoter that is necessary for constitutive and TGFα‐inducible transcriptional activation. In electrophoretic mobility shift assays, this region binds Sp1‐dependent protein complexes constitutively and an additional TGFα‐inducible protein complex that is distinct from Sp1 protein. Both AP‐2 and Egr‐1 transcription factors were detected as components of the TGFα‐inducible protein complex in supershift EMSA studies. In co‐transfection studies, an AP‐2 but not an Egr‐1 expression vector activated VPF/VEGF transcription, thus indicating that AP‐2 protein is functionally important in TGFα‐induced VPF/VEGF gene expression. By clarifying regulatory mechanisms that are critical for angiogenic processes in the skin, these studies may form the basis for new therapeutic strategies to modulate VPF/VEGF expression in cutaneous inflammation and wound healing.

[1]  R. Swerlick,et al.  Differential regulation of vascular cell adhesion molecule-1 gene transcription by tumor necrosis factor alpha and interleukin-1 alpha in dermal microvascular endothelial cells. , 1996, Blood.

[2]  J. Azizkhan,et al.  Transcription from TATA-less promoters: dihydrofolate reductase as a model. , 1993, Critical reviews in eukaryotic gene expression.

[3]  James T. Elder,et al.  Overexpression of transforming growth factor alpha in psoriatic epidermis. , 1989, Science.

[4]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[5]  H. Dvorak,et al.  Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. , 1995, The Journal of investigative dermatology.

[6]  R. Derynck The Physiology Of Transforming Growth Factor-α , 1992 .

[7]  E. Manseau,et al.  Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. , 1995, Journal of immunology.

[8]  J. Fiddes,et al.  Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. , 1989, Biochemical and biophysical research communications.

[9]  G. Breier,et al.  Hypoxia-induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells (*) , 1995, The Journal of Biological Chemistry.

[10]  J. Merchant,et al.  A GC-rich element confers epidermal growth factor responsiveness to transcription from the gastrin promoter , 1991, Molecular and cellular biology.

[11]  Harold L. Moses,et al.  Production and auto-induction of transforming growth factor-α in human keratinocytes , 1987, Nature.

[12]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Gottlieb,et al.  The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor , 1992, The Journal of experimental medicine.

[14]  R. Tjian,et al.  Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. , 1991, Genes & development.

[15]  S. Bunting,et al.  The Regulation of Blood Vessel Growth by Vascular Endothelial Growth Factor , 1995, Annals of the New York Academy of Sciences.

[16]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[17]  M. Detmar Molecular regulation of angiogenesis in the skin. , 1996, The Journal of investigative dermatology.

[18]  K. Thomas Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*) , 1996, The Journal of Biological Chemistry.

[19]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[20]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[21]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  R. Schüle,et al.  Cloning and characterization of a second AP-2 transcription factor: AP-2 beta. , 1995, Development.

[23]  D. Ruiter,et al.  Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. , 1995, The American journal of pathology.

[24]  L. Orci,et al.  Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. , 1992, Biochemical and biophysical research communications.

[25]  V. Sukhatme,et al.  Early growth response protein 1 (Egr-1): prototype of a zinc-finger family of transcription factors. , 1995, Progress in nucleic acid research and molecular biology.

[26]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[27]  Gregory S. Schultz,et al.  EGF and TGF‐α in wound healing and repair , 1991 .

[28]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.

[29]  J. Caro,et al.  Hypoxia regulatory elements of the human vascular endothelial growth factor gene. , 1994, Cellular & molecular biology research.

[30]  J. Hornung,et al.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line , 1988, The Journal of cell biology.

[31]  M. Kan,et al.  Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Dvorak,et al.  Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. , 1993, Archives of biochemistry and biophysics.

[33]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[34]  M. Shibuya Role of VEGF-flt receptor system in normal and tumor angiogenesis. , 1995, Advances in cancer research.

[35]  M. Goldberg,et al.  Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia (*) , 1996, The Journal of Biological Chemistry.

[36]  R. Glockshuber,et al.  An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2 , 1993, Molecular and cellular biology.

[37]  C. Ballaun,et al.  Human keratinocytes express the three major splice forms of vascular endothelial growth factor. , 1995, The Journal of investigative dermatology.

[38]  R. Roeder,et al.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.

[39]  M. Neeman,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.

[40]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[41]  R. Tjian,et al.  Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. , 1989, Genes & development.

[42]  M. Longaker,et al.  Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes. , 1995, The Journal of Biological Chemistry.

[43]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[44]  Vascular Endothelial Growth Factor In Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders , 1995 .

[45]  C. A. Thomas,et al.  Molecular cloning. , 1977, Advances in pathobiology.

[46]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[47]  Georg Breier,et al.  Molecular Mechanisms of Developmental and Tumor Angiogenesis , 1994, Brain pathology.

[48]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[49]  D. Gospodarowicz,et al.  Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells. , 1989, The EMBO journal.

[50]  V. Sukhatme,et al.  A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1 , 1993, Molecular and cellular biology.

[51]  S. Fenton,et al.  Transforming growth factor alpha: expression, regulation, and biological activities. , 1995, Pharmacological reviews.

[52]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[53]  G. Palade,et al.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.

[54]  L. Nanney,et al.  Quantitative determination of EGF-R during epidermal wound healing. , 1992, The Journal of investigative dermatology.

[55]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[56]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[57]  H. Dvorak,et al.  A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. , 1986, Cancer research.

[58]  R. Tjian,et al.  Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. , 1988, Genes & development.

[59]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[60]  I. Ono,et al.  Evaluation of cytokines in donor site wound fluids. , 1994, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[61]  D. Maglione Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .

[62]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[63]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[64]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[65]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[66]  R. Akhurst,et al.  Localization of transforming growth factor‐alpha RNA and protein in the skin of psoriatic patients receiving therapy , 1994, The British journal of dermatology.

[67]  R. Derynck,et al.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. , 1986, Science.

[68]  H. Dvorak,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. , 1995, The Journal of investigative dermatology.

[69]  H. Dvorak,et al.  Vascular permeability factor, tumor angiogenesis and stroma generation. , 1994, Invasion & metastasis.

[70]  Goldman,et al.  Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. , 1993, Molecular biology of the cell.

[71]  M. Karin,et al.  Transcription factor AP-2 mediates induction by two different signal-transduction pathways: Protein kinase C and cAMP , 1987, Cell.